Regeneron

Regeneron’s ultra-rare-disease drug won U.S. regulatory approval after a three-decade effort.

FDA approves Ultragenyx gene therapy and Regeneron secures ultra-rare disease approval, underscoring regulatory momentum for gene therapies and mRNA platforms, per The Readout.

IEEE Presidents’ Scholarship highlights three high-school projects (Tonguage, NeuroGait, and a hexapod) with strong end-user impact and notable cost/tech advantages in assistive robotics.